CITIUS ONCOLOGY, INC.

Citius Oncology, Inc., filing under ticker TENK, is the post-combination entity formed through the de-SPAC merger involving TenX Keane Acquisition Corp., a blank-check company sponsored by TenX Keane Sponsor LLC that completed its initial public offering in 2022 with a focus on the healthcare and oncology sector. Citius Oncology was spun out of Citius Pharmaceuticals and holds oncology biopharmaceutical assets, including an FDA-approved cancer therapy, giving the combined company an operating commercial footprint following the transaction close. The Form 8-K/A filed August 26, 2024 is an amendment to a prior current report, updating public disclosures during the company's post-merger transition. Sign up for full data on SpacDesk to access complete filing histories, sponsor profiles, and deal analytics across the SPAC market.